Study of VS-7375 for KRAS G12D colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new targeted pill, VS-7375, for people with a specific type of advanced colorectal cancer called KRAS G12D. It's for those who either haven't had treatment yet or whose cancer has worsened after prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your colorectal cancer must have spread to other parts of the body and be measurable on scans.
- Your tumor must have a specific genetic change called KRAS G12D mutation, confirmed by a lab test.
- You must be able to do most of your daily activities (ECOG score 0 or 1).
- If you've already had chemotherapy for spread, your cancer must have grown during or after that treatment.
- You cannot have had other RAS gene mutations, prior RAS-targeted treatments, or certain other medications recently.
- You must be able to swallow pills and not have untreated or symptomatic brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug called VS-7375 for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if it can shrink tumors or slow their growth.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This trial tests a combination of two drugs (fulzerasib and cetuximab) given before surgery to shrink locally advanced colorectal cancer that has a specific genetic mutation called KRAS G12C. The goal is to help make the cancer easier to remove surgically and improve outcomes.
This trial tests a new drug, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. It's for those who have already tried chemo and immunotherapy, and whose cancer has continued to grow.
This study tests a new drug called VS-7375, combined with cetuximab, for pancreatic cancer patients whose tumors have a specific genetic mutation called KRAS G12D. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests an experimental drug called PT0253 for people with advanced or metastatic cancers that have a specific genetic change called KRAS G12D. The drug may help shrink or slow the growth of these tumors, and the study will also check for side effects.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.